OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to hepatic inflammation to cirrhosis. We sought to identify common genetic variants contributing to NAFLD, using CT measured fatty liver (FL), and alanine aminotransferase levels (ALT), as a biochemical marker of hepatic inflammation. METHODS: We employed a correlated meta-analysis (CMA) to test whether combining FL and ALT genomewide association (GWA) results, using ∼2.5 million imputed SNPs, could enhance ability to detect variants influencing both traits. RESULTS: Variants of the ERLIN1-CHUK-CWF19L1 gene cluster were associated with concomitant variation of FL and ALT. Nine variants (rs2862954, rs1408579, rs10883451, rs11597086, rs11591741, rs17729876, rs17668255, rs17668357, rs12784396) displayed genomewide significant associations at loci concomitantly influencing FL and ALT (2.47 × 10(-9) ≤ CMA-p ≤ 4.29 × 10(-10)) as compared with the suggestive significance of marginal tests (4.11 × 10(-5) ≤ GWA-p ≤ 2.34 × 10(-6)). For example, the missense variant in ERLIN1-rs2862954 was genomewide significant (CMA-p = 4.88 × 10(-10)) for the combination of FL and ALT, while the respective univariate associations were suggestive (FL:p = 5.74 × 10(-6), ALT:p = 3.71 × 10(-6)). Further we investigated whether the concomitant associations were driven mainly by ALT levels. When we adjusted FL by ALT, the correlated associations diminished but did not vanish (CMA-p ≤ 3.3 × 10(-7)). Our findings suggest ERLIN1-CHUK-CWF19L1 variants are associated with early stage of FL accumulation (measured by CT) to hepatic inflammation (ALT levels), and the association enhances when accounting for the correlations between their scans. CONCLUSIONS: CMA approach enhanced the ability to identify novel variants of the ERLIN1-CHUK-CWF19L1 influencing both simple steatosis and hepatic steatosis with inflammation, which suggest that this gene cluster may regulate the susceptibility of NAFLD in a wide spectrum of disease.
OBJECTIVES:Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to hepatic inflammation to cirrhosis. We sought to identify common genetic variants contributing to NAFLD, using CT measured fatty liver (FL), and alanine aminotransferase levels (ALT), as a biochemical marker of hepatic inflammation. METHODS: We employed a correlated meta-analysis (CMA) to test whether combining FL and ALT genomewide association (GWA) results, using ∼2.5 million imputed SNPs, could enhance ability to detect variants influencing both traits. RESULTS: Variants of the ERLIN1-CHUK-CWF19L1 gene cluster were associated with concomitant variation of FL and ALT. Nine variants (rs2862954, rs1408579, rs10883451, rs11597086, rs11591741, rs17729876, rs17668255, rs17668357, rs12784396) displayed genomewide significant associations at loci concomitantly influencing FL and ALT (2.47 × 10(-9) ≤ CMA-p ≤ 4.29 × 10(-10)) as compared with the suggestive significance of marginal tests (4.11 × 10(-5) ≤ GWA-p ≤ 2.34 × 10(-6)). For example, the missense variant in ERLIN1-rs2862954 was genomewide significant (CMA-p = 4.88 × 10(-10)) for the combination of FL and ALT, while the respective univariate associations were suggestive (FL:p = 5.74 × 10(-6), ALT:p = 3.71 × 10(-6)). Further we investigated whether the concomitant associations were driven mainly by ALT levels. When we adjusted FL by ALT, the correlated associations diminished but did not vanish (CMA-p ≤ 3.3 × 10(-7)). Our findings suggest ERLIN1-CHUK-CWF19L1 variants are associated with early stage of FL accumulation (measured by CT) to hepatic inflammation (ALT levels), and the association enhances when accounting for the correlations between their scans. CONCLUSIONS: CMA approach enhanced the ability to identify novel variants of the ERLIN1-CHUK-CWF19L1 influencing both simple steatosis and hepatic steatosis with inflammation, which suggest that this gene cluster may regulate the susceptibility of NAFLD in a wide spectrum of disease.
Authors: Cody J Boyce; Perry J Pickhardt; David H Kim; Andrew J Taylor; Thomas C Winter; Richard J Bruce; Mary J Lindstrom; J Louis Hinshaw Journal: AJR Am J Roentgenol Date: 2010-03 Impact factor: 3.959
Authors: J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano Journal: Radiology Date: 2005-01 Impact factor: 11.105
Authors: M Higgins; M Province; G Heiss; J Eckfeldt; R C Ellison; A R Folsom; D C Rao; J M Sprafka; R Williams Journal: Am J Epidemiol Date: 1996-06-15 Impact factor: 4.897
Authors: Randall J Pruim; Ryan P Welch; Serena Sanna; Tanya M Teslovich; Peter S Chines; Terry P Gliedt; Michael Boehnke; Gonçalo R Abecasis; Cristen J Willer Journal: Bioinformatics Date: 2010-07-15 Impact factor: 6.937
Authors: Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki Journal: PLoS Genet Date: 2011-03-10 Impact factor: 5.917
Authors: Aldi T Kraja; Dhananjay Vaidya; James S Pankow; Mark O Goodarzi; Themistocles L Assimes; Iftikhar J Kullo; Ulla Sovio; Rasika A Mathias; Yan V Sun; Nora Franceschini; Devin Absher; Guo Li; Qunyuan Zhang; Mary F Feitosa; Nicole L Glazer; Talin Haritunians; Anna-Liisa Hartikainen; Joshua W Knowles; Kari E North; Carlos Iribarren; Brian Kral; Lisa Yanek; Paul F O'Reilly; Mark I McCarthy; Cashell Jaquish; David J Couper; Aravinda Chakravarti; Bruce M Psaty; Lewis C Becker; Michael A Province; Eric Boerwinkle; Thomas Quertermous; Leena Palotie; Marjo-Riitta Jarvelin; Diane M Becker; Sharon L R Kardia; Jerome I Rotter; Yii-Der Ida Chen; Ingrid B Borecki Journal: Diabetes Date: 2011-03-08 Impact factor: 9.461
Authors: Noura S Abul-Husn; Xiping Cheng; Alexander H Li; Yurong Xin; Claudia Schurmann; Panayiotis Stevis; Yashu Liu; Julia Kozlitina; Stefan Stender; G Craig Wood; Ann N Stepanchick; Matthew D Still; Shane McCarthy; Colm O'Dushlaine; Jonathan S Packer; Suganthi Balasubramanian; Nehal Gosalia; David Esopi; Sun Y Kim; Semanti Mukherjee; Alexander E Lopez; Erin D Fuller; John Penn; Xin Chu; Jonathan Z Luo; Uyenlinh L Mirshahi; David J Carey; Christopher D Still; Michael D Feldman; Aeron Small; Scott M Damrauer; Daniel J Rader; Brian Zambrowicz; William Olson; Andrew J Murphy; Ingrid B Borecki; Alan R Shuldiner; Jeffrey G Reid; John D Overton; George D Yancopoulos; Helen H Hobbs; Jonathan C Cohen; Omri Gottesman; Tanya M Teslovich; Aris Baras; Tooraj Mirshahi; Jesper Gromada; Frederick E Dewey Journal: N Engl J Med Date: 2018-03-22 Impact factor: 91.245
Authors: Maria S Nazarenko; Aleksei A Sleptcov; Igor N Lebedev; Nikolay A Skryabin; Anton V Markov; Maria V Golubenko; Iuliia A Koroleva; Anton N Kazancev; Olga L Barbarash; Valery P Puzyrev Journal: Sci Rep Date: 2017-01-25 Impact factor: 4.379
Authors: Aaron Hakim; Matthew Moll; Joseph Brancale; Jiangyuan Liu; Jessica A Lasky-Su; Edwin K Silverman; Silvia Vilarinho; Z Gordon Jiang; Yered H Pita-Juárez; Ioannis S Vlachos; Xuehong Zhang; Fredrik Åberg; Nezam H Afdhal; Brian D Hobbs; Michael H Cho Journal: Hepatology Date: 2021-11-09 Impact factor: 17.298
Authors: Deborah Edelman; Harmit Kalia; Maria Delio; Mustafa Alani; Karthik Krishnamurthy; Mortadha Abd; Adam Auton; Tao Wang; Allan W Wolkoff; Bernice E Morrow Journal: Mol Genet Genomic Med Date: 2015-08-11 Impact factor: 2.183